| Year |
Citation |
Score |
| 2008 |
Sun L, Geng X, Geney R, Li Y, Simmerling C, Li Z, Lauher JW, Xia S, Horwitz SB, Veith JM, Pera P, Bernacki RJ, Ojima I. Design, synthesis, and biological evaluation of novel C14-C3'BzN-linked macrocyclic taxoids. The Journal of Organic Chemistry. 73: 9584-93. PMID 18975909 DOI: 10.1021/Jo801713Q |
0.58 |
|
| 2005 |
Geney R, Chen J, Ojima I. Recent advances in the new generation taxane anticancer agents. Medicinal Chemistry (ShāRiqah (United Arab Emirates)). 1: 125-39. PMID 16787308 DOI: 10.2174/1573406053175292 |
0.547 |
|
| 2005 |
Geney R, Sun L, Pera P, Bernacki RJ, Xia S, Horwitz SB, Simmerling CL, Ojima I. Use of the tubulin bound paclitaxel conformation for structure-based rational drug design. Chemistry & Biology. 12: 339-48. PMID 15797218 DOI: 10.1016/J.Chembiol.2005.01.004 |
0.549 |
|
| 2004 |
Geng X, Geney R, Pera P, Bernacki RJ, Ojima I. Design and synthesis of de novo cytotoxic alkaloids through mimicking taxoid skeleton. Bioorganic & Medicinal Chemistry Letters. 14: 3491-4. PMID 15177459 DOI: 10.1016/J.Bmcl.2004.04.060 |
0.553 |
|
| 2003 |
Ojima I, Geney R. 109881 Aventis. Current Opinion in Investigational Drugs (London, England : 2000). 4: 737-40. PMID 12901234 |
0.428 |
|
| 2003 |
Ojima I, Geney R. BMS-184476 Bristol-Myers Squibb. Current Opinion in Investigational Drugs (London, England : 2000). 4: 732-6. PMID 12901233 |
0.416 |
|
| 2002 |
Geney R, Ungureanu lM, Li D, Ojima I. Overcoming multidrug resistance in taxane chemotherapy. Clinical Chemistry and Laboratory Medicine. 40: 918-25. PMID 12435109 DOI: 10.1515/Cclm.2002.161 |
0.553 |
|
| 2002 |
Ojima I, Geney R, Ungureanu IM, Li D. Medicinal chemistry and chemical biology of new generation taxane antitumor agents. Iubmb Life. 53: 269-74. PMID 12121008 DOI: 10.1080/15216540212658 |
0.534 |
|
| 2002 |
Chuang CY, Vassar VC, Ma Z, Geney R, Ojima I. Electronic effects on the regio- and enantioselectivity of the asymmetric aminohydroxylation of O-substituted 4-hydroxy-2-butenoates. Chirality. 14: 151-62. PMID 11835558 DOI: 10.1002/Chir.10050 |
0.526 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2006 |
Geney R, Layten M, Gomperts R, Hornak V, Simmerling C. Investigation of Salt Bridge Stability in a Generalized Born Solvent Model. Journal of Chemical Theory and Computation. 2: 115-27. PMID 26626386 DOI: 10.1021/Ct050183L |
0.253 |
|
| 2006 |
Okur A, Wickstrom L, Layten M, Geney R, Song K, Hornak V, Simmerling C. Improved Efficiency of Replica Exchange Simulations through Use of a Hybrid Explicit/Implicit Solvation Model. Journal of Chemical Theory and Computation. 2: 420-33. PMID 26626529 DOI: 10.1021/Ct050196Z |
0.24 |
|
| 2013 |
Blanc J, Geney R, Menet C. Type II kinase inhibitors: an opportunity in cancer for rational design. Anti-Cancer Agents in Medicinal Chemistry. 13: 731-47. PMID 23094911 DOI: 10.2174/1871520611313050008 |
0.18 |
|
| 2013 |
Menet CJ, Rompaey LV, Geney R. Advances in the discovery of selective JAK inhibitors. Progress in Medicinal Chemistry. 52: 153-223. PMID 23384668 DOI: 10.1016/B978-0-444-62652-3.00004-1 |
0.091 |
|
| 2014 |
Menet CJ, Fletcher SR, Van Lommen G, Geney R, Blanc J, Smits K, Jouannigot N, Deprez P, van der Aar EM, Clement-Lacroix P, Lepescheux L, Galien R, Vayssiere B, Nelles L, Christophe T, et al. Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634. Journal of Medicinal Chemistry. 57: 9323-42. PMID 25369270 DOI: 10.1021/jm501262q |
0.067 |
|
| Hide low-probability matches. |